Row over SMA drug distribution in Keralam unwarranted, say experts
Experts and hospital authorities in Kerala have dismissed claims that a generic version of the SMA drug Risdiplam being distributed at a state hospital is an experimental drug. The controversy has become a political issue, with opposition leaders questioning the government's decision to switch to a cheaper generic alternative.
Why it matters
The incident highlights the tension between cost-saving measures in public healthcare and public perception of drug safety and clinical standards.
Row over SMA drug distribution in Keralam unwarranted, say experts left SAT Hospital. https://th-i.thgim.com/public/incoming/xfgwnt/article71608008.ece/alternates/FREE_1200/SAT%20Hospital.jpg TH SAT Hospital SAT Hospital authorities deny the claim of parents of SMA children that the drug given free of cost at the hospital clinic was an “experimental drug.” Hospital authorities say what was given was the generic version of Risdiplam, the patented original formula by Roche, now manufactured by the Indian firm Natco Pharma and which has been approved by drug regulatory bodies in the country Thiruvananthapuram The row over the distribution of “experimental drug” meant for “clinical trials” to spinal muscular atrophy (SMA) patients assumed political dimensions in the State, with the Opposition quick to latch on to the issue, demanding that the government assuage the concerns of the parents.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in